Apex Biotechnology

Apex Biotechnology EV/FCF

The EV/FCF (Enterprise Value to Free Cash Flow) of Apex Biotechnology (1733.TW) as of Nov 22, 2026 is 16.48. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was 8.41 — a change of 95.84% (higher).

EV/FCF

16.48

YoY

95.84%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of Apex Biotechnology is 2025 16.48 . EV/FCF (Enterprise Value to Free Cash Flow) of Apex Biotechnology was 2024 8.41 . It decreases by 95.84% higher compared to the previous year.

The Apex Biotechnology EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2018
-391.82 TWD
Jan 1, 2019
6.93 TWD
Jan 1, 2020
11.61 TWD
Jan 1, 2021
17.31 TWD
Jan 1, 2022
-205.75 TWD
Jan 1, 2023
13.07 TWD
Jan 1, 2024
8.41 TWD
Jan 1, 2025
16.48 TWD
The Apex Biotechnology EV/FCF history
YEAREV/FCFYoY
16.48+95.84%
8.41-35.65%
13.07-106.35%
-205.75-1,288.37%
17.31+49.09%
11.61+67.59%
6.93-101.77%
-391.82-694.72%
65.88+521.49%
10.60+70.80%
6.21-58.30%
14.88—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Apex Biotechnology Stock analysis

What does Apex Biotechnology do? Apex Biotechnology Corp is a Taiwan-based company specializing in the development of innovative biotechnology products. The company was founded in 2002 and offers a wide range of products and services to its customers. Apex Biotechnology Corp began with the production of specialty chemicals and enzymes for research and development purposes. Over the years, the company has expanded its business and focused on the development of diagnostic products, dietary supplements, and pharmaceutical products. The company's business model focuses on the development and marketing of biotechnology products. Apex Biotechnology Corp has established advanced research centers and works closely with research institutions and pharmaceutical companies worldwide to develop innovative solutions. The company operates in various sectors, including diagnostics, dietary supplements, and pharmaceuticals. It offers a diverse range of products, including enzyme immunoassays, lateral flow tests, dietary supplements, and pharmaceuticals. Apex Biotechnology Corp has built strong relationships with research institutions and pharmaceutical companies and has successfully marketed its products internationally. Apex Biotechnology is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Apex Biotechnology stock

EV/FCF (Enterprise Value to Free Cash Flow) of Apex Biotechnology is 16.48 in 2025.

EV/FCF (Enterprise Value to Free Cash Flow) of Apex Biotechnology changed from 8.41 to 16.48, representing a 95.84% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) Apex Biotechnology since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s Apex Biotechnology with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Apex Biotechnology

All Key Metrics — Apex Biotechnology